Cheng X, Sun Y, Highkin M, Vemalapally N, et al. Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance. Cancer Res 2023 Jun 5:CAN-22-3558. doi: 10.1158/0008-5472.CAN-22-3558.
PMID: 37272756